Nifty
:
25299.35
Sensex
:
81911.01
44.30 (0.18%)
31.61 (0.04%)
Nifty
Sensex
:
:
25299.35
81911.01
44.30 (0.18%)
31.61 (0.04%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1807.20
12-Nov-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1813.1
  •  1821.1
  •  1785.4
  •  1827.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2274622
  •  4101971339.3
  •  1859.9
  •  1106

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,03,855.71
  • 26.03
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,02,140.19
  • 0.22%
  • 2.64

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.88%
  • 0.59%
  • 5.02%
  • FII
  • DII
  • Others
  • 17.41%
  • 21.20%
  • 3.90%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.48
  • 7.49
  • 5.08

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.10
  • 9.23
  • 3.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.29
  • 5.77
  • 3.37

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.99
  • 20.07
  • 22.15

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.16
  • 1.92
  • 2.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.65
  • 9.60
  • 10.73

Earnings Forecasts:

(Updated: 07-11-2026)
Description
2026
2027
2028
2029
Adj EPS
60.34
81.5
96.29
107.8
P/E Ratio
29.95
22.17
18.77
16.76
Revenue
33384.7
40200.3
44703.9
48329.1
EBITDA
6845.73
8451.03
9635.65
10623.5
Net Income
3504.75
4701.93
5568.37
6244.81
ROA
6.47
8
8.8
2.81
P/B Ratio
2.77
2.52
2.25
2.03
ROE
9.94
11.76
12.48
12.55
FCFF
2827.34
1567.06
3286.84
4411.99
FCFF Yield
2.82
1.56
3.28
4.41
Net Debt
-2544.69
-1757.87
-3963.3
-5859
BVPS
652.39
717.28
801.81
891.27

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 26
Sep 25
Var%
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Net Sales
10,263.29
8,285.70
23.87%
9,150.35
7,868.14
16.30%
8,853.34
8,382.12
5.62%
8,645.90
7,978.52
8.36%
Expenses
8,107.54
6,607.60
22.70%
7,269.29
6,265.11
16.03%
7,100.56
6,590.20
7.74%
6,872.56
6,400.54
7.37%
EBITDA
2,155.75
1,678.10
28.46%
1,881.06
1,603.03
17.34%
1,752.78
1,791.92
-2.18%
1,773.34
1,577.98
12.38%
EBIDTM
21.00%
20.25%
20.56%
20.37%
19.80%
21.38%
20.51%
19.78%
Other Income
168.22
120.59
39.50%
264.23
105.30
150.93%
117.04
134.81
-13.18%
187.64
157.29
19.30%
Interest
102.21
95.24
7.32%
101.66
97.75
4.00%
98.21
115.02
-14.61%
92.77
118.48
-21.70%
Depreciation
531.15
429.19
23.76%
486.82
405.70
20.00%
478.57
444.43
7.68%
464.73
418.53
11.04%
PBT
1,690.61
1,274.26
32.67%
1,516.63
1,204.88
25.87%
1,293.04
1,367.28
-5.43%
1,338.15
1,198.26
11.67%
Tax
563.83
427.79
31.80%
483.06
382.60
26.26%
369.77
432.26
-14.46%
428.72
354.28
21.01%
PAT
1,126.78
846.47
33.12%
1,033.57
822.28
25.70%
923.27
935.02
-1.26%
909.43
843.98
7.75%
PATM
10.98%
10.22%
11.30%
10.45%
10.43%
11.15%
10.52%
10.58%
EPS
19.57
14.61
33.95%
17.95
14.20
26.41%
15.86
15.56
1.93%
15.67
14.56
7.62%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
36,912.88
33,653.08
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
Net Sales Growth
13.53%
6.08%
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
 
Cost Of Goods Sold
14,520.57
12,014.40
11,671.89
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
Gross Profit
22,392.31
21,638.68
20,051.84
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
GP Margin
60.66%
64.30%
63.21%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
Total Expenditure
29,349.95
26,835.75
25,140.94
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
Power & Fuel Cost
-
1,117.61
1,012.25
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
% Of Sales
-
3.32%
3.19%
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
Employee Cost
-
5,190.17
4,475.62
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
% Of Sales
-
15.42%
14.11%
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
Manufacturing Exp.
-
3,760.09
3,556.25
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
% Of Sales
-
11.17%
11.21%
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
General & Admin Exp.
-
1,763.42
1,551.60
1,483.77
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
% Of Sales
-
5.24%
4.89%
5.12%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
Selling & Distn. Exp.
-
2,254.93
2,185.06
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
% Of Sales
-
6.70%
6.89%
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
Miscellaneous Exp.
-
735.13
688.27
700.92
698.93
419.58
576.06
529.75
413.24
298.75
848.43
% Of Sales
-
2.18%
2.17%
2.42%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
EBITDA
7,562.93
6,817.33
6,582.79
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
EBITDA Margin
20.49%
20.26%
20.75%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
Other Income
737.13
520.49
621.85
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
Interest
394.85
383.97
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
Depreciation
1,961.27
1,778.19
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
PBT
5,838.43
5,175.66
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
Tax
1,845.38
1,608.88
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
Tax Rate
31.61%
31.48%
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
PAT
3,993.05
3,504.75
3,485.88
3,172.97
1,927.50
2,648.15
5,334.84
2,845.14
2,364.73
2,423.17
2,301.66
PAT before Minority Interest
3,996.73
3,502.97
3,483.57
3,168.97
1,927.65
2,647.11
5,333.82
2,843.69
2,364.50
2,422.91
2,301.19
Minority Interest
3.68
1.78
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
PAT Margin
10.82%
10.41%
10.99%
10.94%
7.75%
11.29%
21.53%
12.32%
12.09%
14.72%
15.44%
PAT Growth
15.82%
0.54%
9.86%
64.62%
-27.21%
-50.36%
87.51%
20.32%
-2.41%
5.28%
 
EPS
69.40
60.91
60.58
55.14
33.50
46.02
92.72
49.45
41.10
42.11
40.00

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
37,890.97
32,653.32
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
Share Capital
58.08
58.08
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
Total Reserves
37,832.89
32,595.24
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
Non-Current Liabilities
1,096.74
1,162.74
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
Secured Loans
798.20
1,159.38
2,134.90
618.96
249.21
168.49
0.00
48.88
26.96
177.59
Unsecured Loans
4.55
402.27
0.00
0.00
0.00
0.00
0.00
131.07
424.24
3.81
Long Term Provisions
400.41
282.93
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
Current Liabilities
18,039.01
14,682.34
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
Trade Payables
5,567.27
4,188.85
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
Other Current Liabilities
5,828.46
4,462.78
3,161.05
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
Short Term Borrowings
6,079.64
5,470.22
4,078.12
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
Short Term Provisions
563.64
560.49
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
Total Liabilities
57,018.56
48,492.01
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
Net Block
17,406.58
14,794.19
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
Gross Block
29,251.05
24,462.96
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
Accumulated Depreciation
11,844.47
9,668.77
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
Non Current Assets
24,309.81
21,329.55
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
Capital Work in Progress
5,213.56
4,899.96
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
Non Current Investment
303.88
251.70
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
Long Term Loans & Adv.
971.58
973.42
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
Other Non Current Assets
414.21
410.28
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
Current Assets
32,708.75
27,162.46
23,771.92
21,459.91
18,043.59
19,739.90
16,412.51
15,332.30
12,178.16
9,206.18
Current Investments
747.24
0.01
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
Inventories
12,052.94
10,543.72
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
Sundry Debtors
7,094.37
5,745.93
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
Cash & Bank
9,870.29
8,235.49
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
Other Current Assets
2,943.91
654.00
519.45
554.71
1,908.62
1,575.98
1,555.31
2,715.72
1,977.28
1,596.81
Short Term Loans & Adv.
2,545.16
1,983.31
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
Net Current Assets
14,669.74
12,480.12
11,572.79
9,966.13
9,887.61
9,074.85
5,027.87
3,311.73
3,512.27
2,600.58
Total Assets
57,018.56
48,492.01
43,425.16
39,126.74
33,554.03
33,317.70
28,764.54
26,271.07
20,942.24
16,081.66

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
5,526.37
3,924.62
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
PBT
5,111.85
5,066.29
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
Adjustment
2,082.62
1,834.16
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
Changes in Working Capital
163.93
-1,244.48
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
Cash after chg. in Working capital
7,358.40
5,655.97
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,832.03
-1,731.35
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,458.61
-1,875.80
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
Net Fixed Assets
-543.55
-141.97
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
Net Investments
-2,352.78
-1,816.13
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
Others
-562.28
82.30
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
Cash from Financing Activity
-1,269.15
119.78
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
Net Cash Inflow / Outflow
798.61
2,168.60
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
Opening Cash & Equivalents
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
Closing Cash & Equivalent
7,191.40
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
652.39
562.21
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
ROA
6.64%
7.54%
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
ROE
9.93%
11.15%
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
ROCE
12.76%
14.39%
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
Fixed Asset Turnover
2.59
2.65
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
Receivable days
33.71
30.33
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
Inventory Days
59.32
58.44
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
Payable days
148.20
135.14
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
Cash Conversion Cycle
-55.17
-46.37
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
Total Debt/Equity
0.20
0.24
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
Interest Cover
14.31
12.08
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • USFDA classifies Aurobindo Pharma’s arm’s USA facility as official action indicated
    12th Nov 2026, 11:42 AM

    After the completion of inspection, the USFDA had issued four observations

    Read More
  • Aurobindo Pharma’s arm receives USFDA EIR for Telangana facility
    11th Nov 2026, 12:14 PM

    The facility has been classified as Voluntary Action Indicated (VAI) by the USFDA

    Read More
  • Aurobindo Pharma reports 33% rise in Q2 consolidated net profit
    5th Nov 2026, 11:08 AM

    Consolidated total income of the company increased by 24.09% to Rs 10,431.51 crore in Q2FY27

    Read More
  • Aurobindo Pharma gets USFDA’s final nod to manufacture, market Perampanel tablets
    5th Oct 2026, 09:58 AM

    The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company and will be launched in Q3FY27

    Read More
  • USFDA concludes inspection at Aurobindo Pharma’s arm’s Telangana facility
    16th Sep 2026, 12:58 PM

    The inspection concluded with one observation, which is procedural in nature

    Read More
  • Aurobindo Pharma gets USFDA’s nod for Beclomethasone Dipropionate HFA Inhalation Aerosol
    15th Sep 2026, 16:14 PM

    The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    11th Sep 2026, 17:51 PM

    The inspection was conducted from September 7 to September 11, 2026 and concluded with zero observations

    Read More
  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary
    1st Sep 2026, 13:05 PM

    The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

    Read More
  • Aurobindo Pharma’s arm launches generic equivalent of Advair Diskus in US market
    31st Aug 2026, 10:58 AM

    Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    28th Aug 2026, 17:27 PM

    The inspection concluded with three observations, which are procedural in nature

    Read More
  • Aurobindo Pharma’s arm receives four observations from USFDA
    24th Aug 2026, 15:41 PM

    The USFDA conducted a routine inspection at Lannett Company LLC from August 17 to August 21, 2026

    Read More
  • USFDA concludes inspection at Aurobindo Pharma’s AuroPeptides with one observation
    24th Aug 2026, 09:28 AM

    The USFDA conducted inspection at AuroPeptides from August 17 to 21, 2026

    Read More
  • Aurobindo Pharma incorporates wholly owned subsidiary
    14th Aug 2026, 09:06 AM

    The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.